Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
NEW YORK, April 23, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Celgene Corporation ("Celgene") (NASDAQ:CELG) securities between September 12, 2016 and February 27, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/celgene-corporation?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) the trials for GED-0301 suffered from fatal design defects, such that GED-0301 had failed to demonstrate meaningful clinical efficacy; (3) the growth of Otezla sales had dramatically slowed during Celgene's third fiscal quarter of 2017; and (4) the clinical and nonclinical pharmacology data in Celgene's new drug application ("NDA") for Ozanimod were insufficient to permit a complete review by the FDA, which resulted in the FDA issuing a refusal to file letter to Celgene regarding the NDA.
If you suffered a loss in Celgene you have until May 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/celgene-corporation?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
